Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Kindeva Drug Delivery LP
483
•Kindeva Drug Delivery LP•April 3, 2024

Kindeva Drug Delivery LP – FDA 483, Apr 3, 2024

Record Details

During an inspection from April 1-3, 2024, Kindeva Drug Delivery LP, a contract testing laboratory in Woodbury, MN, received an FDA Form 483 detailing significant observations. The primary concerns revolved around deficiencies in laboratory controls and quality unit procedures, particularly impacting the testing of albuterol sulfate MDI.Firstly, the FDA noted inadequate laboratory controls. A method transfer for a purity assay (Method-07-000337) lacked comparability testing between sites and failed to demonstrate the ability to quantify impurities. Additionally, there was no detailed procedure for chromatography data integration, and the system allowed analysts to change integrations without requiring audit trail capture, compromising data integrity.Secondly, the quality control unit’s responsibilities and procedures were found to be insufficient. A standard operating procedure (GSOP-07-000028) for reviewing electronic data, including audit trails, lacked specificity, and expanded audit trail reviews were not performed. Furthermore, unvalidated spreadsheets were used for critical calculations (GSOP-07-000051), violating validation requirements.Finally, the firm failed to maintain backup files for electronic raw data generated from instruments used in release testing for albuterol sulfate MDI, posing a risk to data security and retrievability.These observations highlight deviations from regulatory expectations, indicating a need for Kindeva Drug Delivery LP to implement comprehensive corrective actions to ensure compliance with standards for drug product testing and data integrity.

Company
Kindeva Drug Delivery LP
Inspection date
April 3, 2024
Product type
drugs
Office
Minneapolis District Office
People
  • Shelby N. Turner
  • Lloyd D. Payne (Drug Discovery and Biotech Executive)
  • Joann M (Director)
View Company Profile

ID · 0e22ea50-be1c-45d3-b2d5-6a2c7eb97832

Other documents for Kindeva Drug Delivery LP
  • 483 - 2025-11-13November 13, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kindeva Drug Delivery LP
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.